TESTIMONIALS

“The key finding is the ability of the test to make an early prediction of response and disease control, just three to four weeks after initiation of immunotherapy. The flexibility to switch treatments early on based on an accurate prediction has great potential to improve the treatment of many cancers.”
“If you are able to tell after the first cycle that it isn’t working, it can bring significant savings to the healthcare payer.”
“The basic idea behind our tests is that since each and every cell in the body has its genomic material half from your father and half from your mother, there should not be significant changes to these genetic blueprints with age. However, if cancer cells are present, they are continuously changing their genetic material and their genomic patterns are markedly different from all the other healthy cells in your body. We can specifically detect this cancerous material or mutations in the plasma.“
Prof. Ekkehard Schütz, M.D., Ph.D., FACB, About CNI Tests

MEDICAL PUBLICATIONS

  • Dr hab. n. med. Jakub Dobruch FEBU - liquid biopsy

Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer

Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO. Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion.

  • liquid biopsy - Chronix Biomedical

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Genomic analysis of tissue malignancies is well recapitulated by tumor cell free DNA (cfDNA) using the power of Next Generation Sequencing (NGS).

  • predicting-treatment-outcomes-in-chemotherapy

Predicting Treatment Outcomes in Chemotherapy

Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.

Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.

VIDEOS

Madappa N. Kundranda, MD, PhD. Director, Gastrointestinal Oncology Program, Adjunct Assistant Professor, University of Texas MD Anderson Cancer Center,Banner MD Anderson, Arizona.

Experts on Chronix Biomedical CNI Monitor test. Testing for drug efficacy. #TheTurningPointInCancerFight

Chronix ASCO 2017: Dr Glen Weiss

Experts on Chronix Biomedical CNI Monitor test. Testing for drug [...]

Chronix ASCO 2017: Dr Tomislav Dragovich

Experts on Chronix Biomedical CNI Monitor test. Testing for drug [...]